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A b s t r A c t
Percutaneous coronary intervention (PCI) is an alternative therapeutic modality to 
coronary artery bypass surgery (CABG) for the revascularization of patients with mul-
tivessel coronary artery disease (CAD). Its effectiveness has been questioned because 
of higher rates of repeat revascularization and anginal attacks compared to CABG. 
Over the recent years drug eluting stents (DES) have been used for the management 
of patients with multivessel CAD as a major breakthrough technology in terms of 
a remarkable reduction of restenosis and repeat revascularization. Results from the 
Artery Revascularization Therapies (ARTS II) study indicate that DES and CABG 
have comparative effectiveness in major adverse cardiac events (MACE) in patients 
with multivessel CAD. Whether DES will replace CABG in the revascularization of 
patients with multivessel disease remains to be seen by the impending results of ongo-
ing multicenter comparative trials. 
b A c K G r O U N D
Percutaneous coronary intervention (PCI) with or without coronary stents is an 
alternative to surgery therapeutic modality for mechanical coronary revasculariza-
tion. Procedures involving PCI outnumber surgical procedures involving CABG as 
the most frequent revascularization modality for obstructive coronary artery disease 
(CAD), although the role of PCI has been limited by restenosis rates up to 20% with 
bare metal stents (BMS) [1].
As a consequence, CABG was demonstrated to have better long-term outcomes 
than PCI with BMS and/or balloon angioplasty in two and three vessel CAD. Since 
the introduction of drug eluting stents (DES) which constitute a major breakthrough 
in restenosis reduction, target lesion and vessel revascularization are no longer a 
drawback when treating patients with obstructive CAD.
Indeed, a recently published study (ARTS II) demonstrated that the sirolimus 
eluting stents have comparable rates of major cardiac adverse events (MACE) for 
the treatment of patients with multivessel CAD at three years when compared to 
CABG [2].
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AbbreviAtions And Acronyms
ARTS= Arterial Revascularization 
Therapy Study
CABG= coronary artery bypass grafting
CI= confidence interval
DES= drug-eluting stents
HR= hazard ratio
LAD= left anterior descending coronary 
artery
LIMA= left internal mammary artery
MIDCABG= Minimally invasive direct 
coronary artery bypass graft surgery
PES= paclitaxel-eluting stents
PCI= percutaneous coronary intervention
SES= sirolimus-eluting stents
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P c I  v s  c A b G  I N  t H E  P A s t 
A meta-analysis including nine trials of multivessel CAD 
treated by percutaneous balloon angioplasty alone or CABG 
showed a statistically significant benefit in terms of survival 
in favor of surgery at five and eight years [3]. However, these 
survival data were from early studies that did not use stents 
in the initial revascularization procedure. Nevertheless, the 
Stent or Surgery Trials (SOS), which involved the use of 
stents, reported similar findings after a median follow-up of 
2 years [4].
However, the Angentine Randomized Trial Coronary An-
gioplasty with stenting versus Coronary Bypass Surgery With 
Multivessel Disease (ERACI-II) suggested that the trend in 
favor of CABG for survival at 5 years was no longer present 
in the stent era [5] (Fig. 1). The final analysis of the arterial 
revascularization therapies study (ARTS I) involved the use 
of bare metal stents in patients with multivessel disease versus 
CABG [6]. At five years there was no difference in mortality 
between stenting and surgery for multivessel disease. Further-
more, the incidence of stroke or myocardial infarction was 
not significantly different between the two groups. However, 
overall MACE rate was higher in the stent group, driven by 
the increased need for repeat revascularization (Fig. 2).
P c I  v s  c A b G :  P r E s E N t  A N D  f U t U r E
Are DES equivalent in terms of effectiveness to CABG in 
treating patients with multivessel CAD? For PCI to replace 
CABG as preferred therapy in multivessel CAD, clinical trials 
must demonstrate that long-term outcomes are comparative. 
The problems that must be overcome include restenosis, 
diffuse disease and diabetes. DES reduce restenosis rates 
to less than double digits in non-complex cases raising the 
possibility that perhaps they would also be useful in complex 
cases [7,8].
The Arterial Revascularization Therapies Study II trial 
(ARTS II) is a 45 center, 607 patient single-arm study. Three-
year outcomes were compared to the outcome of the historical 
cohorts of ARTS I using the same inclusion and exclusion 
criteria and MACE definitions. Patients were stratified by 
clinical site to ensure that at least 1/3 had 3 vessel disease to 
achieve a number of treated lesions per patient comparable 
to ARTS I. An angiographic coronary score to characterize 
lesion complexity was applied to allow the identification of 
patients who might benefit the most from multivessel stenting. 
This non-randomized study showed that despite the higher 
clinical angiographic risk profile, the overall MACE rate at 
three years was lower in ARTS II than in the ARTS-I PCI was 
comparable to ARTS-I CABG. However, the re-intervention 
rate in ARTS-I CABG remained significantly lower that in 
ARTS-II [2] (Fig. 3). 
W H A t  I s  N E x t ?
Coronary revascularization methods continue to be re-
fined, so that evaluation of the outcomes of PCI and CABG 
remains a moving target. Randomized trials are underway to 
evaluate whether DES provide outcomes similar to CABG in 
multivessel CAD when technically feasible. FREEDOM and 
CARDIA studies are randomized trials that included diabetic 
patients with three vessel disease examining the long-term ef-
fectiveness of DES in terms of MACE compared to CABG. 
Syntax is a randomized trial that included patients with three 
vessel and or left main disease aiming to determine which is fIGUrE 1. ERACI II 5-year survival curves.
fIGUrE 2. ARTS I, MACE curves over 5 years.
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the most appropriate therapy between DES and CABG.
Awaiting the results of these important studies and in the 
absence of a definitive clinical trial to support the superiority 
of DES over CABG, the prudent cardiologist should rely on 
the facts presented in a recent systematic review study com-
paring the effectiveness of PCI and CABG []. The authors 
of this review concluded that compared with PCI, CABG was 
more effective in relieving angina and led to fewer repeated 
revascularizations but had a higher risk for procedural stroke. 
Survival to 10 years was similar for both procedures.
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fIGUrE 3. ARTS II MACE curves over 3 years.
